www.ijarp.com ISSN 2456-9992 Page: 01-16

International Journal Advanced Research Publications

Review Article

Volume: 02
Issue: 07

CURRENT TRENDS AND FUTURE DIRECTIONS IN PARKINSON'S DISEASE RESEARCH

Ran Vijay Singh[1], Prem Prasad[2], Sanjay Kumar Kushwaha[3]*

[1,2]Associate Professor, Bhavdiya Institute of Pharmaceutical Sciences and Research Ayodhya-224126.

[3]Professor& Director of Bhavdiya Institute of Pharmaceutical Sciences and Research Ayodhya-224126.

Article Received: 23 May 2026, Article Revised: 11 June 2026, Published on: 01 July 2026

***Corresponding Author: Sanjay Kumar Kushwaha**

Professor& Director of Bhavdiya Institute of Pharmaceutical Sciences and Research Ayodhya-224126.

Doi: https://doi-doi.org/101555/ijarp.4839

ABSTRACT

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra and the accumulation of α-synuclein-containing Lewy bodies. It is the second most common neurodegenerative disease worldwide and represents a significant healthcare burden due to its increasing prevalence in aging populations. Despite substantial advances in symptomatic management, no definitive cure or disease-modifying therapy is currently available. Recent research has focused on understanding the complex molecular mechanisms underlying PD, including oxidative stress, mitochondrial dysfunction, neuroinflammation, protein misfolding, and genetic susceptibility. Emerging diagnostic approaches involving biomarkers, neuroimaging techniques, and artificial intelligence-based tools are improving the accuracy of early disease detection. Furthermore, innovative therapeutic strategies such as gene therapy, stem cell therapy, neuroprotective agents, immunotherapy targeting α-synuclein, and nanotechnology-based drug delivery systems are being actively investigated. This review highlights the current trends in Parkinson's disease research, emphasizing recent scientific breakthroughs in pathogenesis, diagnosis, and treatment. Additionally, it discusses future directions and challenges in translating these advances into effective clinical interventions. Continued multidisciplinary research efforts are essential for developing personalized and disease-modifying therapies that can improve patient outcomes and quality of life.

KEYWORDS: Parkinson's disease, Neurodegeneration, α-Synuclein, Biomarkers, Gene therapy, Stem cell therapy, Neuroprotection, Nanotechnology, Precision medicine.

INTRODUCTION

Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects movement and is characterized by the gradual loss of dopaminergic neurons in the substantia nigra pars compacta, a region of the brain responsible for controlling voluntary movement. The depletion of dopamine, an essential neurotransmitter, leads to the development of characteristic motor symptoms, including resting tremor, bradykinesia (slowness of movement), muscular rigidity, and postural instability.**[1]** In addition to these motor manifestations, patients with Parkinson's disease frequently experience a wide range of non-motor symptoms such as depression, anxiety, sleep disturbances, autonomic dysfunction, cognitive impairment, and sensory abnormalities. These symptoms significantly affect the quality of life of patients and contribute to the overall burden of the disease. Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease and represents a major global health challenge. The prevalence of PD has increased substantially over recent decades, largely due to increased life expectancy and the aging population. According to recent estimates, millions of people worldwide are living with Parkinson's disease, and the number is expected to rise significantly in the coming years.**[2]** This growing prevalence places a substantial economic and social burden on healthcare systems, caregivers, and affected individuals. Consequently, understanding the underlying mechanisms of Parkinson's disease and developing effective therapeutic strategies remain critical priorities in neurological research. Although the exact cause of Parkinson's disease remains unclear, extensive research has revealed that the disease results from a complex interaction of genetic, environmental, and aging-related factors.**[3]** Several genetic mutations, including those in the SNCA, LRRK2, PARKIN, PINK1, and DJ-1 genes, have been associated with familial forms of Parkinson's disease. Environmental risk factors such as exposure to pesticides, heavy metals, industrial toxins, and traumatic brain injury have also been implicated in disease development.**[4]** Furthermore, advancing age remains the strongest risk factor, suggesting that age-related cellular dysfunction plays a crucial role in disease progression. One of the major pathological hallmarks of Parkinson's disease is the abnormal accumulation of alpha-synuclein protein, which forms intracellular aggregates known as Lewy bodies. The aggregation of alpha-synuclein is believed to contribute to neuronal dysfunction and death through mechanisms involving oxidative stress, mitochondrial

impairment, neuroinflammation, protein misfolding, and disruption of cellular homeostasis. Over the past decade, significant progress has been made in understanding these molecular pathways, providing valuable insights into disease pathogenesis and identifying potential therapeutic targets.**[5]** Traditionally, the management of Parkinson's disease has focused primarily on symptomatic treatment. Levodopa remains the gold-standard therapy and is widely used to improve motor symptoms by replenishing dopamine levels in the brain. Other pharmacological agents, including dopamine agonists, monoamine oxidase-B inhibitors, catechol-O-methyltransferase inhibitors, and anticholinergic drugs, are also employed to manage symptoms. In advanced stages of the disease, surgical interventions such as deep brain stimulation have demonstrated considerable benefits in selected patients.**[6]** However, these treatment approaches primarily address symptoms and do not halt or reverse the underlying neurodegenerative process. As a result, there is a growing need for disease-modifying therapies capable of slowing or preventing disease progression. Recent advances in biomedical research have transformed the landscape of Parkinson's disease investigation. The emergence of advanced neuroimaging techniques, molecular biomarkers, genomic technologies, and artificial intelligence-based diagnostic tools has improved the ability to detect the disease at earlier stages and monitor its progression more accurately. Biomarkers derived from cerebrospinal fluid, blood, imaging studies, and genetic analyses are increasingly being explored for their potential in early diagnosis and personalized medicine approaches.**[7]** At the same time, innovative therapeutic strategies are being actively developed. Gene therapy aims to correct or modify disease-related genetic abnormalities, while stem cell-based therapies seek to replace lost dopaminergic neurons and restore neurological function. Immunotherapy targeting alpha-synuclein aggregation has shown promise in preclinical and clinical studies, offering a novel approach to disease modification. Additionally, nanotechnology-based drug delivery systems are being investigated to improve the delivery of therapeutic agents across the blood-brain barrier, thereby enhancing treatment efficacy and reducing adverse effects. The growing understanding of the molecular and cellular mechanisms underlying Parkinson's disease has opened new avenues for research and therapeutic innovation. Nevertheless, significant challenges remain, including the identification of reliable biomarkers, the development of effective disease-modifying therapies, and the translation of experimental findings into clinical practice.**[8]** Therefore, continued multidisciplinary research efforts are essential to address these challenges and improve patient outcomes. This review discusses the current trends in Parkinson's disease research, focusing on recent advances in disease pathogenesis, diagnostic technologies,

emerging therapeutic approaches, and future directions. By examining the latest developments in the field, this review aims to provide a comprehensive overview of ongoing research efforts and highlight promising strategies that may contribute to more effective and personalized management of Parkinson's disease in the future.[9]



Figure 1. Overview of Parkinson's disease.

1. Overview of Parkinson's disease in the future as a Progressive Neurodegenerative Disorder

Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the gradual loss of dopaminergic neurons in the substantia nigra of the brain and the accumulation of α-synuclein protein aggregates known as Lewy bodies. It is the second most common neurodegenerative disorder worldwide and primarily affects older adults, with its prevalence increasing as the global population ages.The disease is characterized by both motor and non-motor symptoms.**[10]** The cardinal motor manifestations include resting tremor, bradykinesia, muscular rigidity, and postural instability, while non-motor symptoms such as depression, cognitive impairment, sleep disturbances, autonomic dysfunction, and sensory abnormalities significantly impact patients' quality of life. The progression of Parkinson's disease is associated with several pathological mechanisms, including oxidative stress, mitochondrial dysfunction, neuroinflammation, protein misfolding, and neuronal degeneration, ultimately leading to dopamine

depletion.Although the exact etiology of Parkinson's disease remains unclear, both genetic and environmental factors contribute to its development. Mutations in genes such as SNCA, LRRK2, PARKIN, and PINK1 have been linked to familial forms of the disease, whereas exposure to pesticides, heavy metals, and environmental toxins may increase disease risk.**[11]**Current treatment strategies primarily focus on symptomatic management through medications such as levodopa, dopamine agonists, and MAO-B inhibitors, along with surgical interventions like Deep Brain Stimulation (DBS). However, these therapies do not halt disease progression. Recent advances in biomarker discovery, neuroimaging, artificial intelligence, gene therapy, stem cell therapy, immunotherapy, and nanotechnology-based drug delivery systems have opened new avenues for early diagnosis and disease modification.**[12]**

Table: Parkinson's Disease – Types, Treatment, and References.

S. No.	Disease Type	Treatment	Reference
1	Sporadic Parkinson's Disease (Late-Onset PD)	Levodopa/Carbidopa, Dopamine agonists, MAO-B inhibitors, COMT inhibitors, Deep Brain Stimulation (DBS)	**[13]**
2	Early-Onset Parkinson's Disease	Dopamine agonists, MAO-B inhibitors, Physiotherapy, Lifestyle modification, Genetic counseling	**[14]**
3	Genetic/Hereditary Parkinson's Disease	Symptomatic therapy, Genetic counseling, Gene-targeted therapies (under investigation)	**[15]**
4	Advanced/Progressive Parkinson's Disease	Deep Brain Stimulation (DBS), Apomorphine infusion, Levodopa-Carbidopa intestinal gel (LCIG), Multidisciplinary care	**[16]**
5	Non-Motor Symptom Dominant PD	Antidepressants, Cognitive enhancers, Sleep disorder management, Autonomic dysfunction treatment	**[17]**
6	Refractory/Fluctuating Parkinson's Disease	DBS, LCIG therapy, Amantadine, Continuous medication optimization	**[18]**
7	Future/Emerging Parkinson's Disease Therapies	Gene therapy, Stem cell therapy, Immunotherapy, Nanotechnology-based drug delivery, Neuroprotective agents	**[19]**
8	Parkinson's Disease with Cognitive Impairment	Rivastigmine, Cognitive rehabilitation, Supportive therapy	**[20]**

2. Parkinson's Disease: Global Prevalence and Increasing Burden

Parkinson's disease (PD) is one of the fastest-growing neurological disorders worldwide and represents a major public health challenge. It is the second most common neurodegenerative

disease after Alzheimer's Disease and affects millions of individuals globally. The prevalence of Parkinson's disease has increased substantially over the past few decades, primarily due to population aging, increased life expectancy, environmental risk factors, and improved diagnostic capabilities.**[21]**Globally, more than 10 million people are estimated to be living with Parkinson's disease, and this number is expected to rise significantly in the coming decades. The disease predominantly affects individuals over the age of 60 years, although early-onset cases can also occur. Epidemiological studies indicate that the prevalence of Parkinson's disease increases with age, affecting approximately 1% of people over 60 years and up to 4–5% of those above 85 years. Men are generally more likely to develop the disease than women, suggesting the influence of genetic, hormonal, and environmental factors.**[22]**The growing burden of Parkinson's disease extends beyond its clinical manifestations. Patients often experience progressive disability, loss of independence, reduced quality of life, and increased risk of hospitalization. In addition to motor symptoms such as tremor, rigidity, and bradykinesia, non-motor symptoms including depression, cognitive impairment, sleep disorders, and autonomic dysfunction contribute significantly to disease burden. These complications require long-term medical care and continuous support from caregivers and healthcare systems.**[23]**The economic impact of Parkinson's disease is substantial, involving direct medical expenses, rehabilitation costs, long-term care requirements, and productivity losses. As the global population continues to age, the number of affected individuals is expected to increase dramatically, placing additional pressure on healthcare resources worldwide. Consequently, Parkinson's disease has emerged as a major socioeconomic challenge requiring coordinated public health strategies.Given its rising prevalence and growing burden, there is an urgent need for improved early diagnosis, effective disease-modifying therapies, and innovative treatment approaches. Continued research into the causes, progression, and management of Parkinson's disease is essential to reduce its impact on patients, caregivers, and society while improving long-term clinical outcomes.**[24]**

Table: Parkinson's Disease Global Prevalence and Increasing Burden.

S. No.	Region/Country	Prevalence and Burden	Reference
1	Global	More than 10 million people are living with Parkinson's disease worldwide, making it the second most common neurodegenerative disorder after Alzheimer's disease.	**[25]**

S. No.	Region/Country	Prevalence and Burden	Reference
2	North America	Increasing prevalence due to aging populations and improved diagnostic capabilities. Parkinson's disease is a major cause of disability among older adults.	**[26]**
3	Europe	High prevalence among individuals aged over 60 years, with a growing healthcare and economic burden.	**[27]**
4	Asia	Rapid increase in cases due to population aging, urbanization, and longer life expectancy.	**[28]**
5	India	Parkinson's disease prevalence is steadily increasing because of demographic changes and increased life expectancy.	**[29]**
6	China	One of the largest Parkinson's disease populations globally due to its aging population.	**[30]**
7	Low- and Middle-Income Countries	Growing disease burden with limited access to specialized neurological care and treatment facilities.	**[31]**
8	Elderly Population (>60 years)	Approximately 1% of individuals over 60 years are affected, with prevalence increasing significantly with age.	**[32]**
9	Elderly Population (>80 years)	Prevalence may exceed 4–5%, making Parkinson's disease a major geriatric health concern.	**[33]**
10	Future Projections	The number of Parkinson's disease cases is expected to double by 2040–2050 due to population aging and increased survival rates.	**[34]**



Figure 3. Parkinson's disease improvein the patient.

4. Importance of Modern Therapeutic Approaches

Modern therapeutic approaches have become increasingly important in the management of Parkinson's disease (PD) due to the progressive nature of the disorder and the limitations of conventional treatments. Traditional therapies, such as levodopa and dopamine agonists, primarily provide symptomatic relief but do not prevent the ongoing degeneration of dopaminergic neurons.**[35]** As a result, there is a growing need for innovative treatment strategies that can slow disease progression, improve patient outcomes, and enhance quality of life.Recent advances in Parkinson's disease research have led to the development of several promising therapeutic approaches. Gene therapy aims to modify disease-related genetic abnormalities and restore normal cellular function. Stem cell therapy offers the potential to replace damaged dopaminergic neurons and promote neural regeneration. Immunotherapy targeting α-synuclein aggregation seeks to reduce the formation of toxic protein deposits that contribute to neuronal death. Additionally, neuroprotective agents are being investigated to protect neurons from oxidative stress, mitochondrial dysfunction, and neuroinflammation.**[36]**Nanotechnology-based drug delivery systems have also emerged as a valuable strategy for improving the delivery of therapeutic agents across the blood–brain barrier, thereby increasing treatment efficacy and reducing adverse effects. Furthermore, advances in biomarker research, artificial intelligence, and precision medicine are enabling earlier diagnosis and the development of personalized treatment plans tailored to individual patient needs.**[37]**The importance of these modern therapeutic approaches lies in their potential to move beyond symptomatic management and address the underlying causes of Parkinson's disease. By targeting disease mechanisms and promoting neuroprotection or regeneration, these innovative strategies may ultimately lead to more effective disease-modifying therapies, improved functional outcomes, and a better quality of life for patients living with Parkinson's disease.**[38]**

Table: Importance of Modern Therapeutic Approaches in Parkinson's Disease.

S. No.	Modern Therapeutic Approach	Importance/Benefits	Reference
1	Levodopa-Based Therapy	Gold-standard treatment for improving motor symptoms such as tremor, rigidity, and bradykinesia.	**[39]**
2	Dopamine Agonists	Stimulate dopamine receptors and help reduce motor fluctuations in early-stage PD.	**[40]**
3	Deep Brain Stimulation (DBS)	Improves motor control and quality of life in advanced Parkinson's disease patients.	**[41]**

S. No.	Modern Therapeutic Approach	Importance/Benefits	Reference
4	Gene Therapy	Targets disease-causing genetic abnormalities and offers potential disease-modifying effects.	**[42]**
5	Stem Cell Therapy	Aims to replace lost dopaminergic neurons and promote neural regeneration.	**[43]**
6	Immunotherapy	Targets α-synuclein aggregation to reduce neurodegeneration and disease progression.	**[44]**
7	Neuroprotective Agents	Protect neurons from oxidative stress, mitochondrial dysfunction, and neuroinflammation.	**[45]**
8	Nanotechnology-Based Drug Delivery	Enhances drug delivery across the blood–brain barrier and improves therapeutic efficacy.	**[46]**
9	Biomarker-Based Diagnostics	Facilitates early diagnosis and monitoring of disease progression.	**[47]**
10	Artificial Intelligence and Precision Medicine	Enables personalized treatment strategies, disease prediction, and improved patient management.	**[48]**

Table no.3:*Importance of Modern Therapeutic Approaches for Improving the Diagnosis, Treatment, and Management of Parkinson's Disease*

5. Aim and Scope of the Review

The growing impact of Parkinson's disease (PD) on global health has made it essential to continuously evaluate current research developments and therapeutic strategies. Over the past few decades, significant progress has been achieved in understanding the molecular mechanisms, pathological processes, and clinical manifestations of Parkinson's disease. These advancements have provided valuable insights into the complex pathogenesis of the disorder and have created new opportunities for the development of innovative therapeutic approaches aimed at improving disease management and patient outcomes.**[49]**The primary aim of this review is to provide a comprehensive overview of Parkinson's disease, with particular emphasis on current trends and future directions in research. This review highlights recent scientific developments in disease pathogenesis, biomarker discovery, neuroimaging technologies, and emerging therapeutic strategies designed to slow, halt, or modify disease progression. By examining contemporary research findings, this review aims to present a clear understanding of how modern scientific advancements are shaping the future of Parkinson's disease diagnosis and treatment.**[50]**In addition to conventional pharmacological therapies, including levodopa, dopamine agonists, and monoamine oxidase-B inhibitors, this review explores emerging therapeutic approaches such as gene therapy, stem cell therapy,

immunotherapy targeting α-synuclein aggregation, neuroprotective agents, and nanotechnology-based drug delivery systems. Furthermore, non-pharmacological interventions, rehabilitation programs, physiotherapy, lifestyle modifications, and supportive care strategies are discussed as important components of comprehensive disease management.The role of emerging technologies, including biomarker-based diagnostics, advanced neuroimaging techniques, wearable monitoring devices, and artificial intelligence-assisted disease detection, is also examined as part of modern approaches to Parkinson's disease management. These innovations have the potential to facilitate early diagnosis, improve disease monitoring, and support personalized treatment strategies.**[51]**This review also aims to identify existing challenges and research gaps in the development of effective disease-modifying therapies for Parkinson's disease. Despite substantial advances in understanding the disease, many promising therapeutic approaches remain under clinical investigation, and further research is required to establish their long-term safety, efficacy, and accessibility. Significant challenges remain in translating experimental discoveries into successful clinical applications.The scope of this review is to summarize current knowledge, highlight recent advancements, and provide insights into future directions for improving the diagnosis, treatment, and overall management of Parkinson's disease.**[52]** The information presented may serve as a valuable resource for researchers, clinicians, pharmacists, and healthcare professionals involved in the study and treatment of this complex neurodegenerative disorder. Additionally, for emerging therapies and ongoing clinical developments, relevant studies and clinical trials published between 2015 and 2025 were reviewed to ensure the inclusion of recent advances and significant findings while excluding irrelevant or outdated reports.**[53]**

7. CONCLUSION

Parkinson's disease is a progressive neurodegenerative disorder that continues to pose significant clinical, social, and economic challenges worldwide. The increasing prevalence of the disease, particularly among aging populations, highlights the urgent need for improved diagnostic and therapeutic strategies. Although conventional treatments such as levodopa, dopamine agonists, and deep brain stimulation remain effective for symptomatic management, they do not prevent the underlying neurodegenerative process.Recent advances in Parkinson's disease research have greatly enhanced our understanding of disease pathogenesis, including the roles of α-synuclein aggregation, mitochondrial dysfunction, oxidative stress, neuroinflammation, and genetic factors. These discoveries have facilitated

the development of innovative therapeutic approaches such as gene therapy, stem cell therapy, immunotherapy, neuroprotective agents, and nanotechnology-based drug delivery systems. In addition, emerging technologies including biomarker-based diagnostics, advanced neuroimaging, wearable monitoring devices, and artificial intelligence are improving early detection and enabling more personalized treatment strategies.Despite these promising developments, several challenges remain in translating experimental findings into effective disease-modifying therapies. Continued multidisciplinary research, large-scale clinical trials, and collaborative efforts between researchers, clinicians, and healthcare organizations are essential to overcome these limitations. Future studies should focus on early diagnosis, neuroprotection, disease modification, and regenerative medicine approaches to improve long-term patient outcomes.

In conclusion, the future of Parkinson's disease management lies in the integration of innovative therapeutic strategies, precision medicine, and advanced diagnostic technologies. These advances offer hope for more effective treatments, improved quality of life, and ultimately the development of interventions capable of slowing or preventing disease progression.

REFERENCES

1. Stocchi, F., Bravi, D., Emmi, A., & Antonini, A. (2024). Parkinson disease therapy: current strategies and future research priorities. *Nature Reviews Neurology*, *20*(12), 695-707.
2. Gouda, N. A., Elkamhawy, A., & Cho, J. (2022). Emerging therapeutic strategies for Parkinson's disease and future prospects: A 2021 update. *Biomedicines*, *10*(2), 371.
3. Chaudhary, S. A., Chaudhary, S., & Rawat, S. (2025). Understanding Parkinson's disease: current trends and its multifaceted complications. *Frontiers in Aging Neuroscience*, *17*, 1617106.
4. Lang, A. E., &Espay, A. J. (2018). Disease modification in Parkinson's disease: current approaches, challenges, and future considerations. *Movement Disorders*, *33*(5), 660-677.
5. Langston, J. W. (2002). Parkinson's disease: current and future challenges. *Neurotoxicology*, *23*(4-5), 443-450.
6. Papagiouvannis, G., Theodosis-Nobelos, P., & Rekka, E. A. (2025). A review on therapeutic strategies against Parkinson's disease: current trends and future perspectives. *Mini-Reviews in Medicinal Chemistry*, *25*(2), 96-111.

7. Kontakos, N., & Stokes, J. (1999). Monograph series on aging-related diseases, 12: Parkinson's disease, recent developments and new directions. *Health Promotion and Chronic Disease Prevention in Canada*, *20*(2), 58.
8. Tenchov, R., Sasso, J., & Zhou, Q. A. (2024). The Evolving Landscape of Parkinson's Disease Research: Current Challenges and Future Outlook.
9. Ramirez-Zamora, A., & Molho, E. (2014). Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions. *Expert Review of Neurotherapeutics*, *14*(1), 93-103.
10. Andersen, J. K. (2026). Implications of cellular senescence in Parkinson's disease: Recent developments and future directions. *Current Opinion in Neurobiology*, *98*, 103173.
11. Greene, J. G. (2012). Current status and future directions of gene expression profiling in Parkinson's disease. *Neurobiology of disease*, *45*(1), 76-82.
12. Titova, N., & Chaudhuri, K. R. (2017). Nonmotor Parkinson's and future directions. *International Review of Neurobiology*, *134*, 1493-1505.
13. Krithiga, L. (2025, November). A Comprehensive Survey of Machine Learning Techniques for Parkinson's Disease Prediction: Trends, Challenges, and Future Directions. In *2025 International Conference on Intelligent Computing, Information and Control Systems (ICOIICS)* (pp. 1310-1316). IEEE.
14. Fukaya, C., & Yamamoto, T. (2015). Deep brain stimulation for Parkinson's disease: recent trends and future direction. *Neurologia medico-chirurgica*, *55*(5), 422-431.
15. Macerollo, A., Zrinzo, L., Akram, H., Foltynie, T., & Limousin, P. (2020). Subthalamic nucleus deep brain stimulation for Parkinson's disease: current trends and future directions. *Expert review of medical devices*, *17*(10), 1063-1074.
16. Walker, L., Stefanis, L., &Attems, J. (2019). Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies–current issues and future directions. *Journal of neurochemistry*, *150*(5), 467-474.
17. Thomas, M., Lenka, A., & Kumar Pal, P. (2017). Handwriting analysis in Parkinson's disease: current status and future directions. *Movement disorders clinical practice*, *4*(6), 806-818.
18. Lan, J., Zhang, L., Gong, L., Lu, K., Deng, J., & Qiu, L. (2026). Trends and challenges in imaging research of Parkinson's disease: a 10-year bibliometric analysis. *Psychoradiology*, kkag018.

19. Leon-Rojas, J. E. (2025). The global rise in Parkinson's disease: a critical analysis of causes and future directions. *Frontiers in Public Health*, *13*, 1606732.
20. Lauretani, F., Longobucco, Y., Ravazzoni, G., Gallini, E., Salvi, M., & Maggio, M. (2021). Imaging the functional neuroanatomy of Parkinson's disease: clinical applications and future directions. *International Journal of Environmental Research and Public Health*, *18*(5), 2356.
21. Kalia, L. V., Berg, D., Kordower, J. H., Shannon, K. M., Taylor, J. P., Cardoso, F., ... & Fung, V. S. (2024). International Parkinson and Movement Disorder Society viewpoint on biological frameworks of Parkinson's disease: current status and future directions. *Movement Disorders*, *39*(10), 1710-1715.
22. SILVER, J. Deep Brain Stimulation for Parkinson's Disease: A Comprehensive Review of Current Paradigms, Emerging Technologies, and Future Directions in a Global Context.
23. Bouhadoun, S., Delva, A., Schwarzschild, M. A., & Postuma, R. B. (2025). Preparing for Parkinson's disease prevention trials: Current progress and future directions. *Journal of Parkinson's Disease*, 1877718X251334050.
24. Rinaldi, D. (2025). Motor and non-motor symptoms in advanced Parkinson's disease: current insights and future directions.
25. Garg, D., & Dhamija, R. K. (2020). Rehabilitation in Parkinson's disease: current status and future directions. *Annals of Movement Disorders*, *3*(2), 79-85.
26. Grasselli, S., Andolfi, A., Di Lisa, D., & Pastorino, L. (2025). In vitro electrophysiological characterization of Parkinson's disease: Challenges, advances, and future directions. *Frontiers in Neuroscience*, *19*, 1584555.
27. Goldman, J. G., Vernaleo, B. A., Camicioli, R., Dahodwala, N., Dobkin, R. D., Ellis, T., ... & Simmonds, D. (2018). Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. *npj Parkinson's Disease*, *4*(1), 19.
28. Li, X., Wei, W., Wang, Y., Wang, Q., & Liu, Z. (2022). Global trend in the research and development of acupuncture treatment on Parkinson's disease from 2000 to 2021: a bibliometric analysis. *Frontiers in neurology*, *13*, 906317.
29. Castonguay, A. M., Gravel, C., & Lévesque, M. (2021). Treating Parkinson's disease with antibodies: Previous studies and future directions. *Journal of Parkinson's Disease*, *11*(1), 71-92.

30. Tan, A. H., Hor, J. W., Chong, C. W., & Lim, S. Y. (2021). Probiotics for Parkinson's disease: Current evidence and future directions. *JGH Open*, *5*(4), 414-419.
31. Picillo, M., Moccia, M., Spina, E., Barone, P., & Pellecchia, M. T. (2016). Biomarkers of Parkinson's disease: recent insights, current challenges, and future prospects. *Journal of Parkinsonism and Restless Legs Syndrome*, 1-13.
32. Cerneckis, J., Ming, G. L., Song, H., He, C., & Shi, Y. (2024). The rise of epitranscriptomics: recent developments and future directions. *Trends in pharmacological sciences*, *45*(1), 24-38.
33. Grasselli, S., Andolfi, A., Di Lisa, D., & Pastorino, L. (2025). In vitro electrophysiological characterization of Parkinson's disease: Challenges, advances, and future directions. *Frontiers in Neuroscience*, *19*, 1584555.
34. Krithiga, L. (2025, November). A Comprehensive Survey of Machine Learning Techniques for Parkinson's Disease Prediction: Trends, Challenges, and Future Directions. In *2025 International Conference on Intelligent Computing, Information and Control Systems (ICOIICS)* (pp. 1310-1316). IEEE.
35. Fukaya, C., & Yamamoto, T. (2015). Deep brain stimulation for Parkinson's disease: recent trends and future direction. *Neurologia medico-chirurgica*, *55*(5), 422-431.
36. Macerollo, A., Zrinzo, L., Akram, H., Foltynie, T., & Limousin, P. (2020). Subthalamic nucleus deep brain stimulation for Parkinson's disease: current trends and future directions. *Expert review of medical devices*, *17*(10), 1063-1074.
37. Walker, L., Stefanis, L., &Attems, J. (2019). Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies–current issues and future directions. *Journal of neurochemistry*, *150*(5), 467-474.
38. Thomas, M., Lenka, A., & Kumar Pal, P. (2017). Handwriting analysis in Parkinson's disease: current status and future directions. *Movement disorders clinical practice*, *4*(6), 806-818.
39. Lan, J., Zhang, L., Gong, L., Lu, K., Deng, J., & Qiu, L. (2026). Trends and challenges in imaging research of Parkinson's disease: a 10-year bibliometric analysis. *Psychoradiology*, kkag018.
40. Leon-Rojas, J. E. (2025). The global rise in Parkinson's disease: a critical analysis of causes and future directions. *Frontiers in Public Health*, *13*, 1606732.
41. Lauretani, F., Longobucco, Y., Ravazzoni, G., Gallini, E., Salvi, M., & Maggio, M. (2021). Imaging the functional neuroanatomy of Parkinson's disease: clinical

applications and future directions. *International Journal of Environmental Research and Public Health*, *18*(5), 2356.

42. Kalia, L. V., Berg, D., Kordower, J. H., Shannon, K. M., Taylor, J. P., Cardoso, F., ... & Fung, V. S. (2024). International Parkinson and Movement Disorder Society viewpoint on biological frameworks of Parkinson's disease: current status and future directions. *Movement Disorders*, *39*(10), 1710-1715.
43. Yue, Y., Zhang, X., Lv, W., Lai, H. Y., & Shen, T. (2023). Interplay between the glymphatic system and neurotoxic proteins in Parkinson's disease and related disorders: current knowledge and future directions. *Neural Regeneration Research*, *19*(9), 1973.
44. Schumacher-Schuh, A. F., Bieger, A., Okunoye, O., Mok, K. Y., Lim, S. Y., Bardien, S., ... & Sarmiento, I. J. K. (2022). Underrepresented populations in Parkinson's genetics research: current landscape and future directions. *Movement Disorders*, *37*(8), 1593-1604.
45. Jin, Y., Ren, R., Tian, X., & Ye, D. (2026). The rising tide of frailty in Parkinson's disease: a bibliometric study of global research landscape and emerging trends. *Frontiers in Neurology*, *17*, 1720699.
46. Adrissi, J., & Fleisher, J. (2022). Moving the dial toward equity in Parkinson's disease clinical research: a review of current literature and future directions in diversifying PD clinical trial participation. *Current neurology and neuroscience reports*, *22*(8), 475-483.
47. Isaacson, S. H., &Citrome, L. (2022). Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions. *Expert Opinion on Drug Safety*, *21*(7), 873-879.
48. Sokol, L. L., Young, M. J., Paparian, J., Kluger, B. M., Lum, H. D., Besbris, J., ... & Cerf, M. (2019). Advance care planning in Parkinson's disease: ethical challenges and future directions. *npj Parkinson's Disease*, *5*(1), 24.
49. Li, X., Zhang, L., Yang, J., & Teng, F. (2024). Role of artificial intelligence in medical image analysis: A review of current trends and future directions. *Journal of Medical and Biological Engineering*, *44*(2), 231-243.
50. Joutsa, J., Corp, D. T., & Fox, M. D. (2022). Lesion network mapping for symptom localization: recent developments and future directions. *Current opinion in neurology*, *35*(4), 453.
51. Schaeffer, E., Becktepe, J. S., Brockmann, K., Eggers, C., Gülke, E., Kalbe, E., ... & Berg, D. (2026). Preventing Parkinson's disease in the context of movement disorders: a

narrative review of current evidence and future directions. *Neurological research and practice*, *8*(1), 27.

52. Adrissi, J., & Fleisher, J. (2022). Moving the dial toward equity in Parkinson's disease clinical research: a review of current literature and future directions in diversifying PD clinical trial participation. *Current neurology and neuroscience reports*, *22*(8), 475-483.
53. Matsui, H., & Takahashi, R. (2024). Current trends in basic research on Parkinson's disease: from mitochondria, lysosome to α-synuclein. *Journal of Neural Transmission*, *131*(6), 663-674.